Abstract
The target tissue for most cancer therapeutics is metastatic disease, either the treatment of overt metastases or the prevention of colonization by micrometastases in the adjuvant setting. Despite this, few drugs are tested in the metastatic setting in preclinical experiments, and relatively little
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have